From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

ZMapp Ebola Drug Granted Fast Track Status by FDA

by Global Biodefense Staff
September 20, 2015

The U.S. Food and Drug Administration has granted ZMapp “Fast Track” designation for the treatment of Ebola virus disease.

The drug famously came into the public spotlight in 2014 after being administered on an emergency basis to Dr. Kent Brantly, a U.S. citizen infected with the Ebola virus in Liberia and evacuated to Emory University Hospital in Georgia.

The special designation is granted to drugs which are determined, based on nonclinical or clinical data, to have the potential to address an unmet medical need and that are intended to treat a serious condition.

Fast Track designation allows for certain benefits, including opportunities for frequent interactions with the FDA, which may enable designated drugs to reach market sooner. Mapp Biopharmaceutical has been working to develop a therapy to treat Ebola virus for more than a decade.

“We have been consulting frequently with the FDA during the development of ZMapp and are grateful for their willingness to work with us to provide interactive review. The formalization of this through Fast Track designation is an important milestone,” said Dr. Larry Zeitlin, President of LeafBio and Mapp.

Development of ZMapp is currently funded with a $24.9 million contract from the Biomedical Advanced Research and Development Authority (BARDA).

Prior to this designation, the FDA had granted ZMapp “orphan drug” designation, which provides financial and other regulatory incentives meant to encourage development of drugs and other products targeted at rare diseases. The goal of both of these designations is to encourage researchers and scientists to research and develop treatments for diseases that may otherwise be overlooked.

Fast Track designation may shorten the path toward filing and obtaining approval of a Biologics License Application, the marketing application that must be filed with and approved by the FDA before ZMapp may be marketed in the United States. The designation does not affect the ongoing clinical trial of ZMapp currently taking place in West Africa.

“We are gratified to receive this designation for ZMapp,” added Dr. Kevin Whaley, CEO of LeafBio and Mapp. “We are hopeful that this step will accelerate access to ZMapp once safety and efficacy are demonstrated to FDA’s satisfaction in ongoing clinical trials.”

Mapp Pharmaceuticals was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. As these products transition to clinical evaluation, LeafBio assumes ownership and commercialization responsibilities.

ZMapp is a trademarked, protected term of Mapp Pharmaceuticals and LeafBio.

From Our Partners
Tags: AntiviralsASPRBARDAEbolaEmerging ThreatsHHS

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
Biosecurity

Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies

June 14, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC